BioNxt Solutions Inc. (CSE:BNXT)

Canada flag Canada · Delayed Price · Currency is CAD
0.630
+0.030 (5.00%)
At close: Feb 27, 2026
26.00%
Market Cap 81.55M
Revenue (ttm) 15.82K
Net Income (ttm) -6.18M
Shares Out 129.44M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,670
Average Volume 79,042
Open 0.640
Previous Close 0.600
Day's Range 0.630 - 0.640
52-Week Range 0.380 - 1.100
Beta 1.28
RSI 53.42
Earnings Date Mar 26, 2026

About BioNxt Solutions

BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis; BNT23002 for the treatment of myasthenia gravis; BNT24002, a sublingual thin film for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-aging; and BNT24004 for the treatment of semaglutide. It also offers diagnostic screening tests; new a... [Read more]

Sector Healthcare
Founded 2017
Employees 20
Stock Exchange Canadian Securities Exchange
Ticker Symbol BNXT
Full Company Profile

Financial Performance

In 2024, BioNxt Solutions's revenue was 26,985, a decrease of -92.75% compared to the previous year's 372,247. Losses were -5.31 million, -31.22% less than in 2023.

Financial Statements

News

There is no news available yet.